• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Advances in targeted therapy: safety of biological agents.靶向治疗的进展：生物制剂的安全性。
Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii34-6. doi: 10.1136/ard.62.suppl_2.ii34.
2
Serious infections with antirheumatic therapy: are biologicals worse?抗风湿治疗引发的严重感染：生物制剂的情况更糟吗？
Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii54-7. doi: 10.1136/ard.2006.058503.
3
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.类风湿关节炎的抗肿瘤坏死因子α治疗：安全性最新进展
Ann Rheum Dis. 2004 Dec;63(12):1538-43. doi: 10.1136/ard.2004.024737. Epub 2004 Jul 8.
4
Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.类风湿关节炎中抗TNF抗体治疗引发严重感染和恶性肿瘤的风险
JAMA. 2006 Nov 8;296(18):2203; author reply 2203-4. doi: 10.1001/jama.296.18.2203-a.
5
Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.类风湿关节炎患者使用抗TNF抗体治疗时发生严重感染和恶性肿瘤的风险。
JAMA. 2006 Nov 8;296(18):2202; author reply 2203-4. doi: 10.1001/jama.296.18.2202.
6
Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.类风湿关节炎患者接受抗TNF抗体治疗时发生严重感染和恶性肿瘤的风险。
JAMA. 2006 Nov 8;296(18):2201; author reply 2203-4. doi: 10.1001/jama.296.18.2201-a.
7
Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis.类风湿关节炎患者在接受抗肿瘤坏死因子治疗时出现中性粒细胞减少症。
Ann Rheum Dis. 2006 Dec;65(12):1678-9. doi: 10.1136/ard.2006.056176.
8
Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.类风湿关节炎患者接受抗TNF抗体治疗时发生严重感染和恶性肿瘤的风险。
JAMA. 2006 Nov 8;296(18):2201-2; author reply 2203-4. doi: 10.1001/jama.296.18.2201-b.
9
Risk of lymphoma in patients with RA treated with anti-TNFalpha agents.使用抗TNFα药物治疗的类风湿关节炎患者患淋巴瘤的风险。
Ann Rheum Dis. 2005 May;64(5):657-8. doi: 10.1136/ard.2005.035311.
10
Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis.类风湿关节炎患者使用肿瘤坏死因子阻断剂治疗期间的生存率
Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii30-3. doi: 10.1136/ard.62.suppl_2.ii30.

引用本文的文献

1
Laryngeal tuberculosis in patients treated with adalimumab: a casual or causal connection?阿达木单抗治疗患者的喉结核：偶然关联还是因果关联？
BMJ Case Rep. 2023 Apr 11;16(4):e254742. doi: 10.1136/bcr-2023-254742.
2
Association between Immunosuppressive Therapy Utilized in the Treatment of Autoimmune Disease or Transplant and Cancer Progression.用于治疗自身免疫性疾病或移植的免疫抑制疗法与癌症进展之间的关联。
Biomedicines. 2022 Dec 30;11(1):99. doi: 10.3390/biomedicines11010099.
3
Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19.癌症与新冠疫情中免疫反应的生物学及可利用交叉点
Biomedicines. 2022 Oct 19;10(10):2628. doi: 10.3390/biomedicines10102628.
4
Knowledge mapping of targeted immunotherapy for myasthenia gravis from 1998 to 2022: A bibliometric analysis.从 1998 年到 2022 年针对重症肌无力的靶向免疫治疗的知识图谱：文献计量分析。
Front Immunol. 2022 Sep 29;13:998217. doi: 10.3389/fimmu.2022.998217. eCollection 2022.
5
Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview.风湿性疾病生物制药的药物警戒、不良事件、发展及展望：概述
Biomedicines. 2020 Aug 23;8(9):303. doi: 10.3390/biomedicines8090303.
6
Regulation of T-Cell Signaling by Post-Translational Modifications in Autoimmune Disease.自身免疫性疾病中 T 细胞信号转导的翻译后修饰调控。
Int J Mol Sci. 2018 Mar 12;19(3):819. doi: 10.3390/ijms19030819.
7
Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis.英夫利昔单抗治疗强直性脊柱炎的长期安全性和疗效
Ther Clin Risk Manag. 2015 Nov 19;11:1719-26. doi: 10.2147/TCRM.S55928. eCollection 2015.
8
Infliximab: 12 years of experience.英夫利昔单抗：12 年的经验。
Arthritis Res Ther. 2011 May 25;13 Suppl 1(Suppl 1):S2. doi: 10.1186/1478-6354-13-S1-S2.
9
TNF-alpha and its inhibitors in cancer.肿瘤坏死因子-α及其抑制剂在癌症中的作用。
Med Oncol. 2010 Jun;27(2):185-98. doi: 10.1007/s12032-009-9190-3. Epub 2009 Mar 11.
10
Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience.抗TNF治疗强直性脊柱炎：芬兰的经验。
Clin Rheumatol. 2007 Oct;26(10):1693-700. doi: 10.1007/s10067-007-0574-5. Epub 2007 Mar 1.

本文引用的文献

1
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.英夫利昔单抗而非依那西普可诱导克罗恩病患者固有层T淋巴细胞凋亡。
Gastroenterology. 2003 Jun;124(7):1774-85. doi: 10.1016/s0016-5085(03)00382-2.
2
Case reports of heart failure after therapy with a tumor necrosis factor antagonist.肿瘤坏死因子拮抗剂治疗后发生心力衰竭的病例报告。
Ann Intern Med. 2003 May 20;138(10):807-11. doi: 10.7326/0003-4819-138-10-200305200-00008.
3
Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives.类风湿性关节炎患者及其一级亲属患恶性淋巴瘤的风险。
Arthritis Rheum. 2003 Apr;48(4):963-70. doi: 10.1002/art.10939.
4
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.英夫利昔单抗治疗可诱导克罗恩病固有层T淋巴细胞凋亡。
Gut. 2002 Feb;50(2):206-11. doi: 10.1136/gut.50.2.206.
5
Prescription-event monitoring and reporting of adverse drug reactions.处方事件监测与药品不良反应报告。
Lancet. 2001 Dec 1;358(9296):1872-3. doi: 10.1016/S0140-6736(01)06898-2.
6
Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway.英夫利昔单抗通过半胱天冬酶依赖性途径诱导慢性活动性克罗恩病患者单核细胞凋亡。
Gastroenterology. 2001 Nov;121(5):1145-57. doi: 10.1053/gast.2001.28702.
7
Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study.类风湿关节炎患者的疾病活动度与淋巴瘤风险：巢式病例对照研究。
BMJ. 1998 Jul 18;317(7152):180-1. doi: 10.1136/bmj.317.7152.180.
8
Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study.全科医疗中对新上市（“黑三角”）药物疑似药物不良反应报告不足的情况：观察性研究。
BMJ. 1998 Jul 11;317(7151):119-20. doi: 10.1136/bmj.317.7151.119.
9
Rheumatoid arthritis and cancer risk.
Eur J Cancer. 1996 Sep;32A(10):1753-7. doi: 10.1016/0959-8049(96)00210-9.
10
Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994.药物警戒：失而复得还是推迟到来？1994年威廉·威瑟林讲座
J R Coll Physicians Lond. 1995 Jan-Feb;29(1):41-9.

Advances in targeted therapy: safety of biological agents.

作者信息

Keystone E C

机构信息

Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, The Joseph and Wolf Lebovic Building, 2nd Floor, Room 2-006, 60 Murray Street, Toronto, Ontario M5G 1X5, Canada.

出版信息

Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii34-6. doi: 10.1136/ard.62.suppl_2.ii34.

DOI:10.1136/ard.62.suppl_2.ii34
PMID:14532146
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1766742/
Abstract
摘要